Back

SGLT2 blockers in AF: the best AAD ever?

3 April 2022 (18:17 - 18:29)
Organised by:
Congress Presentation Part of: Atrial fibrillation (AF) in HFrEF, HFmrEF and HFpEF: does it make any difference? Heart Failure in Atrial Fibrillation EHRA Premium Access EHRA 2022

About the speaker

Photo
Professor Frank Ruschitzka

University Hospital Zurich, Zurich (Switzerland)

4 More presentations in this session

Presentation thumbnail
AF in HFrEF, HFmrEF and HFpEF: does it make any difference?
Professor R. De Boer (Rotterdam, NL)
Slides Video
Presentation thumbnail
Insights from the Castle AF: why was it positive?
Professor N. Marrouche (New Orleans, US)
Slides Video
Presentation thumbnail
The future of AF ablation in heart failure.
Professor D. Gupta (Liverpool, GB)
Slides Video
Presentation thumbnail
Atrial Fibrillation (AF) in HFrEF, HFmrEF and HFpEF: does it make any difference? - discussion.
Video

Access the full session

Session thumbnail
Atrial fibrillation (AF) in HFrEF, HFmrEF and HFpEF: does it make any difference?
Video

The Event

Event poster

EHRA 2022

3 April 2022 18:17 CET
You may be interested in
thumbnail
Congress Presentation
The impact of optimal heart failure therapy on prevention of atrial fibrillation
14 April 2026
thumbnail
Congress Session
SGLT2 inhibitors across the spectrum of heart failure
21 May 2022
thumbnail
Congress Session
Insights into arrhythmia mechanisms
26 August 2022
thumbnail
Congress Presentation
Heart failure and hypertension management today and tomorrow
31 August 2024

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources